Our Current Clinical Trials
We’re actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or a loved one might be a good candidate for our trials, we encourage you to reach out directly via the link below.
Reach out to learn more
Ozekibart (INBRX-109) is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.
The Phase 2 trial for ozekibart (INBRX-109) is currently enrolling patients with unresectable or metastatic conventional chondrosarcoma.
The Phase 1 trial for ozekibart (INBRX-109) is currently enrolling combination treatment cohorts in Ewing sarcoma and colorectal cancer.
Phase 1 Trial
INBRX-106
Hexavalent OX40 Agonist
INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, which is currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.
The Phase 2/3 trial for INBRX-106 is currently enrolling patients with treatment-naive HNSCC with high PD-L1 expression.
The Phase 1/2 trial for INBRX-106 is currently enrolling patients with NSCLC and HNSCC.
Phase 2/3 Trial Phase 1/2 Trial